FDA approves a second Alzheimer’s drug that can modestly slow disease | Morning in America 

U.S. officials have approved
another Alzheimer’s drug that can modestly slow the disease, providing a new option for patients in the early stages of the incurable, memory-destroying ailment.
The Food and Drug Administration approved Eli Lilly’s Kisunla on Tuesday for mild or early cases of dementia caused by Alzheimer’s. It’s only the second drug that’s been convincingly shown to delay cognitive decline in patients, following last year’s approval of a similar drug from Japanese drugmaker Eisai.
#Alzheimer’s
Start your day with "Morning in America," NewsNation's live three-hour national weekend morning newscast hosted by Hena Doba. Saturday and Sunday starting at 7a/6C. #MorningInAmerica
NewsNation is your source for fact-based, unbiased news for all America.
More from NewsNation: www.newsnationnow.com/
Get our app: trib.al/TBXgYpp
Find us on cable: trib.al/YDOpGyG
How to watch on TV or streaming: trib.al/Vu0Ikij